Pharmaceutical

Request for TOC Request for Sample
BUY NOW

North America Genital Warts Market – Industry Trends and Forecast to 2028

Pharmaceutical | Published Report | Aug 2021 | North America | 350 Pages | No of Tables: 98 | No of Figures: 53

Report Description

North America Genital Warts Market, By Morphology (Cauliflower-Like, Smooth Papular, Keratotic, and Flat Warts), Type (Prevention, Diagnostics, Treatment), Cause (HPV 6, HPV 11, Others), Location (Vulva, Cervix Uteri, Urethra, Anus, Scrotum), Gender (Male and Female), Dosage (Cream, Gel, Ointment, Intramuscularly and Others), End-User (Hospitals, Diagnostic Centers, Surgical Centers, Ambulatory Surgical Centers, and Others), Distribution Channel (Direct Tender, Pharmacy Stores and Others), By  Country (U.S., Canada & Mexico) Market Trends and Forecast to 2028.

Get Exclusive Sample Copy of this Report Here

Market Analysis and Insights: North America Genital Warts Market

 North America genital warts market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses that the market is growing with a CAGR of 6.7% in the forecast period of 2021 to 2028 and is expected to reach USD  5,263.90 million by 2028 from USD  3,218.82 million in 2020.

Genital warts are one of the most recurrent types of sexually transmitted infections. The human papillomavirus is the virus responsible for causing genital warts. People will get infected with at least one type of human papillomavirus (HPV) at some point during their lives. Genital warts affect most of the moist tissues in the genital areas of male and female patients. Although the genital infection is asymptomatic, it's frequently recognized as genital warts due to the onset of symptoms. It is estimated that around 1% of sexually active men and women in the United States have genital warts.

Genital warts are caused due to the human papillomavirus (HPV). There are around 30-40 strains of HPV. However, only a few of the strains cause genital warts. The virus is easily transmittable through skin-to-skin contact. Hence it's considered a sexually transmitted infection (STI). The Center for Disease Control and Prevention (CDC) says that people get genital warts due to the mutant activity of HPV.

The surge in prevalence of sexually transmitted diseases (STDs) and human papillomavirus infections in the U.S. rise in the male population, rise of government initiatives and awareness programs in Canada for treatment of genital warts and STDs. The rise in clinical trials, rise in healthcare expenditure and strategic initiatives by market players, and huge market potential in the U.S. and Canada bolsters the genital warts market growth.  However, the increased cost of treatment for genital warts, the side effects noticed while undergoing treatment for genital warts, and lack of patient and consumer awareness are the restraints that could hinder the market growth. The rise in product recalls associated with vaccines, and topical administration of genital warts, and patient compliance regarding the use of vaccines are the restraints that could hinder the market growth.

The North America genital warts market report provides details of market share, new developments, and product pipeline analysis, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological The genital warts market report provides details of market share, new developments, and impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario, contact us for an Analyst Brief. Our team will help you create a revenue impact solution to achieve your desired goal.

Get Exclusive Sample Copy of this Report Here

North America Genital Warts Market Scope and Market Size

  • On the basis of morphology, the North Americagenital warts market is segmented into flat warts, smooth papular, cauliflower-like, and keratotic. In 2021, the cauliflower-like segment is expected to dominate the North America genital warts market due to the high prevalence of cauliflower shapes observed in male patients and ease of identification and treatment.
  • On the basis of type, the North Americagenital warts market is segmented into prevention, diagnostics, and treatment. In 2021, the prevention segment is expected to dominate the North America genital warts market as the prevention is increased due to the availability of Gardasil and Cervarix vaccines and better immunity of the patients in the U.S.
  • On the basis of cause, the North Americagenital warts market is segmented into HPV 6, HPV 11, and others. In 2021, the HPV 6 segment is expected to dominate the North Americagenital warts market owing to the HPV 6 strain having the highest abundance in the number of cases and have a higher prevalence rate than HPV 11.
  • On the basis of location, the North America genital warts market is segmented into cervix uteri, urethra, anus, vulva, and scrotum. In 2021, the vulva segment is expected to dominate the North Americagenital warts market because the prevalence rate in women is higher than the men, and vulva have the softest tissue and secretory glands.
  • On the basis of gender, the North America genital warts market is segmented into male and female. In 2021, the female segment is expected to dominate the North America genital warts market due to the higher prevalence or incidence rate in females and rise in the female population.
  • On the basis of dosage, the North America genital warts market is further sub-segmented into cream, gel, ointment, intramuscularly, and others. In 2021, the cream segment is expected to dominate the North Americagenital warts market because treatment with cream is the easiest way to treat genital warts and ease of administration.
  • On the basis of end-users, the North America genital warts market is segmented into hospitals, diagnostic centers, surgical centers, ambulatory surgical centers, and others. In 2021, the hospitals' segment is expected to dominate the North America genital warts market as hospitals patients have all the facilities as they can directly contact to doctors, which can diagnose the disease and take the effective treatment with the advice of doctors who are experts and rise in healthcare expenditure in the U.S.
  • On the basis of distribution channels, the North America genital warts market is segmented into direct tender, pharmacy stores, and others. In 2021, the direct tender segment is expected to dominate the North Americagenital warts market as there is no requirement for the prescription of doctors and a rise in the number of wholesalers.

North America Genital Warts Market Country Level Analysis

The North America genital warts market is analyzed, and market size information is provided by the product, method, wound type, end-user.

The countries covered in the North America genital warts market report are the U.S., Canada, and Mexico.

  • In 2021, U.S. is dominating due to the presence of the largest consumer market with high GDP. Moreover, the U.S. has the highest household spending in the world and offers trade agreements with several countries making it the largest market for consumer products, including dandruff treatment products, due to the presence of major market players and increased technological advancement in the region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of North America brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of sales channels are considered while providing forecast analysis of the country data.  

The Growth Potential For Genital Wartsin Emerging Economies And The Strategic Initiatives By Market Players Are Creating New Opportunities In The North America Genital Wartsmarket

North America genital warts market also provides you with detailed market analysis for every country growth in a particular industry with the genital warts sales, impact of advancement in genital warts, and changes in regulatory scenarios with their support for the genital warts market. The data is available for the historic period 2010 to 2019.

Competitive Landscape and North America Genital Warts Market Share Analysis

North America genital warts market competitive landscape provides details by a competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width, and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company's focus related to the genital warts market.

The major companies providing the genital warts are Bausch Health Companies Inc., CryoSurgery, Inc., Merck Sharpe & Dohme Corp., a subsidiary of Merck & Co., Inc, Taro Pharmaceutical Industries Ltd, Glenmark Pharmaceutical Inc., USA (a subsidiary of Glenmark Pharmaceuticals Ltd., Edge Pharma, CryoConcepts LP, GlaxoSmithKline plc, ANI Pharmaceuticals, Inc., Verrica Pharmaceuticals, Novan, Inc, Serum Institute of India Pvt. Ltd, Fotona, Orgenesis Inc, Perrigo Company plc, among others.

DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

The strategic initiatives by market players along with new technological advancements for North America genital warts are bridging the gap for the treatment of chronic lung diseases.

For instance,

  • In June 2021,  ANI Pharmaceuticals, Inc. had presented its product portfolio at the Raymond James Human Health Innovation Conference 2021. The conference attended by the company would help the company deliver knowledge about the topical products used to treat genital warts.

Collaboration, joint ventures, and other strategies by the market player are enhancing the company market in the genital warts market, which also provides the benefit for an organization to improve their offering for North America genital warts market.


SKU-

Table of Content

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF THE NORTH AMERICA GENITAL WARTS MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITATIONS

1.6 MARKETS COVERED

2 NORTH AMERICA GENITAL WARTS MARKET: SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 DBMR TRIPOD DATA VALIDATION MODEL

2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.6 MULTIVARIATE MODELLING

2.7 DISTRIBUTION CHANNEL LIFELINE CURVE

2.8 DBMR MARKET POSITION GRID

2.9 VENDOR SHARE ANALYSIS

2.1 MARKET END USER COVERAGE GRID

2.11 SECONDARY SOURCES

2.12 ASSUMPTIONS

3 EXECUTIVE SUMMARY

5 EPIDEMIOLOGY

6 PORTER'S FIVE FORCES MODEL

7 PESTEL ANALYSIS

8 PIPELINE ANALYSIS: NORTH AMERICA GENITAL WARTS MARKET

9 NORTH AMERICA GENITAL WARTS MARKET: REGULATIONS

9.1 CANADA

9.2 U.S.

9.3 EUROPE

9.4 JAPAN

9.5 MALAYSIA

9.6 VIETNAM

9.7 SOUTH AMERICA

10 MARKET OVERVIEW

10.1 DRIVERS

10.1.1 RISE IN PREVALENCE OF SEXUALLY TRANSMITTED DISEASES AND HUMAN PAPILLOMAVIRUS (HPV) VIRUS

10.1.2 RISE OF MALE POPULATION

10.1.3 RISE IN GOVERNMENT INITIATIVES AND AWARENESS PROGRAMMES

10.1.4 RISE IN CLINICAL TRIALS

10.1.5 RISE IN HEALTHCARE EXPENDITURE

10.2 RESTRAINTS

10.2.1 RISE IN COST FOR GENITAL WARTS TREATMENT

10.2.2 SIDE EFFECTS OBSERVED WHILE UNDERGOING THE TREATMENT FOR GENITAL WARTS

10.2.3 LACK OF PATIENT AND CONSUMER AWARENESS

10.2.4 LESS DIAGNOSTIC RATE

10.3 OPPORTUNITIES

10.3.1 USE OF LASER TREATMENT AND CRYOTHERAPY FOR TREATMENT OF GENITAL WARTS.

10.3.2 STRATEGIC INITIATIVES BY MARKET PLAYERS.

10.3.3 RESEARCH AND DEVELOPMENT FOR GENERIC MEDICATIONS

10.4 CHALLENGES

10.4.1 RISE IN PRODUCT RECALL.

10.4.2 PATIENT COMPLIANCE REGARDING THE USE OF VACCINES AND OINTMENTS FOR TREATMENT OF GENITAL WARTS

11 IMPACT OF COVID-19 ON NORTH AMERICA GENITAL WARTS MARKET

11.1 IMPACT ON PRICE

11.2 IMPACT ON DEMAND

11.3 IMPACT ON SUPPLY CHAIN

11.4 STRATEGIC DECISIONS BY MANUFACTURERS

11.5 CONCLUSION

12 NORTH AMERICA GENITAL WARTS MARKET, BY MORPHOLOGY

12.1 OVERVIEW

12.2 CAULIFLOWER-LIKE

12.3 SMOOTH PAPULAR

12.4 KERATOTIC

12.5 FLAT WARTS

13 NORTH AMERICA GENITAL WARTS MARKET, BY TYPE

13.1 OVERVIEW

13.2 PREVENTION

13.3 DIAGNOSTIC

13.3.1 HPV TEST

13.3.2 PAP TEST

13.4 TREATMENT

13.4.1 PHARMACOLOGICAL TREATMENT

13.4.1.1 Imiquimod

13.4.1.2 Podophyllin and Podofilox

13.4.1.3 Trichloroacetic Acid

13.4.1.4 Sinecatechins

13.4.1.5 others

13.4.2 NON- PHARMACOLOGICAL TREATMENT

13.4.2.1 Cryotherapy

13.4.2.2 Electrocautery

13.4.2.3 Laser Treatment

13.4.2.4 Surgical Excision

13.4.3 GARDASIL

13.4.4 CERVARIX

14 NORTH AMERICA GENITAL WARTS MARKET, BY CAUSE

14.1 OVERVIEW

14.2 HPV 6

14.3 HPV 11

14.4 OTHERS

15 NORTH AMERICA GENITAL WARTS MARKET, BY LOCATION

15.1 OVERVIEW

15.2 VULVA

15.3 CERVIX UTERI

15.4 URETHRA

15.5 ANUS

15.6 SCROTUM

16 NORTH AMERICA GENITAL WARTS MARKET, BY GENDER

16.1 OVERVIEW

16.2 FEMALE

16.3 MALE

17 NORTH AMERICA GENITAL WARTS MARKET, BY DOSAGE

17.1 OVERVIEW

17.2 CREAM

17.3 GEL

17.4 OINTMENT

17.5 INTRAMUSCULARLY

17.6 OTHERS

18 NORTH AMERICA GENITAL WARTS MARKET, BY END USER

18.1 OVERVIEW

18.2 HOSPITALS

18.3 DIAGNOSTIC CENTERS

18.4 SURGICAL CENTERS

18.5 AMBULATORY SURGICAL CENTERS

18.6 OTHERS

19 NORTH AMERICA GENITAL WARTS MARKET, BY DISTRIBUTION CHANNEL

19.1 OVERVIEW

19.2 DIRECT TENDER

19.3 PHARMACY STORES

19.4 OTHERS

20 NORTH AMERICA GENITAL WARTS MARKET, BY REGION

20.1 NORTH AMERICA

20.1.1 U.S.

20.1.2 CANADA

20.1.3 MEXICO

21 NORTH AMERICA GENITAL WARTS MARKET: COMPANY LANDSCAPE

21.1 COMPANY SHARE ANALYSIS: NORTH AMERICA

22 SWOT ANALYSIS

23 COMPANY PROFILE

23.1 MERCK SHARP & DOHME CORP., A SUBSIDIARY OF MERCK & CO., INC.

23.1.1 COMPANY SNAPSHOT

23.1.2 REVENUE ANALYSIS

23.1.3 COMPANY SHARE ANALYSIS

23.1.4 PRODUCT PORTFOLIO

23.1.5 RECENT DEVELOPMENT

23.2 GLAXOSMITHKLINE PLC

23.2.1 COMPANY SNAPSHOT

23.2.2 REVENUE ANALYSIS

23.2.3 COMPANY SHARE ANALYSIS

23.2.4 PRODUCT PORTFOLIO

23.2.5 RECENT DEVELOPMENTS

23.3 BAUSCH HEALTH COMPANIES INC.

23.3.1 COMPANY SNAPSHOT

23.3.2 REVENUE ANALYSIS

23.3.3 COMPANY SHARE ANALYSIS

23.3.4 PRODUCT PORTFOLIO

23.3.5 RECENT DEVELOPMENTS

23.4 ANI PHARMACEUTICALS, INC.

23.4.1 COMPANY SNAPSHOT

23.4.2 REVENUE ANALYSIS

23.4.3 COMPANY SHARE ANALYSIS

23.4.4 PRODUCT PORTFOLIO

23.4.5 RECENT DEVELOPMENTS

23.5 BIONTECH SE

23.5.1 COMPANY SNAPSHOT

23.5.2 REVENUE ANALYSIS

23.5.3 COMPANY SHARE ANALYSIS

23.5.4 PRODUCT PORTFOLIO

23.5.5 RECENT DEVELOPMENTS

23.6 CASSIOPEA, INC.

23.6.1 COMPANY SNAPSHOT

23.6.2 PRODUCT PORTFOLIO

23.6.3 RECENT DEVELOPMENTS

23.7 CRYOCONCEPTS LP

23.7.1 COMPANY SNAPSHOT

23.7.2 PRODUCT PORTFOLIO

23.7.3 RECENT DEVELOPMENT

23.8 CRYOIQ

23.8.1 COMPANY SNAPSHOT

23.8.2 PRODUCT PORTFOLIO

23.8.3 RECENT DEVELOPMENT

23.9 CRYOSURGERY, INC.

23.9.1 COMPANY SNAPSHOT

23.9.2 PRODUCT PORTFOLIO

23.9.3 RECENT DEVELOPMENT

23.1 EDGE PHARMA

23.10.1 COMPANY SNAPSHOT

23.10.2 PRODUCT PORTFOLIO

23.10.3 RECENT DEVELOPMENT

23.11 FOTONA

23.11.1 COMPANY SNAPSHOT

23.11.2 PRODUCT PORTFOLIO

23.11.3 RECENT DEVELOPMENTS

23.12 GLENMARK PHARMACEUTICAL INC., USA (A SUBSIDIARY OF GLENMARK PHARMACEUTICALS LTD.)

23.12.1 COMPANY SNAPSHOT

23.12.2 REVENUE ANALYSIS

23.12.3 PRODUCT PORTFOLIO

23.12.4 RECENT DEVELOPMENT

23.13 NOVAN, INC.

23.13.1 COMPANY SNAPSHOT

23.13.2 REVENUE ANALYSIS

23.13.3 PRODUCT PORTFOLIO

23.13.4 RECENT DEVELOPMENTS

23.14 ORGENESIS INC.

23.14.1 COMPANY SNAPSHOT

23.14.2 REVENUE ANALYSIS

23.14.3 PRODUCT PORTFOLIO

23.14.4 RECENT DEVELOPMENT

23.15 PERRIGO COMPANY PLC

23.15.1 COMPANY SNAPSHOT

23.15.2 REVENUE ANALYSIS

23.15.3 PRODUCT PORTFOLIO

23.15.4 RECENT DEVELOPMENT

23.16 SERUM INSTITUTE OF INDIA PVT. LTD.

23.16.1 COMPANY SNAPSHOT

23.16.2 PRODUCT PORTFOLIO

23.16.3 RECENT DEVELOPMENT

23.17 TARO PHARMACEUTICAL INDUSTRIES LTD.

23.17.1 COMPANY SNAPSHOT

23.17.2 REVENUE ANALYSIS

23.17.3 PRODUCT PORTFOLIO

23.17.4 RECENT DEVELOPMENT

23.18 VERRICA PHARMACEUTICALS

23.18.1 COMPANY SNAPSHOT

23.18.2 REVENUE ANALYSIS

23.18.3 PRODUCT PORTFOLIO

23.18.4 RECENT DEVELOPMENTS

24 QUESTIONNAIRE

25 RELATED REPORTS

List of Table

LIST OF TABLES

TABLE 1 NORTH AMERICA GENITAL WARTS MARKET, PIPELINE ANALYSIS

TABLE 2 NORTH AMERICA GENITAL WARTS MARKET, BY MORPHOLOGY, 2019-2028 (USD MILLION)

TABLE 3 NORTH AMERICA CAULIFLOWER-LIKE IN GENITAL WARTS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 4 NORTH AMERICA SMOOTH PAPULAR IN GENITAL WARTS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 5 NORTH AMERICA KERATOTIC IN GENITAL WARTS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 6 NORTH AMERICA FLAT WARTS IN GENITAL WARTS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 7 NORTH AMERICA GENITAL WARTS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 8 NORTH AMERICA PREVENTION IN GENITAL WARTS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 9 NORTH AMERICA DIAGNOSTIC IN GENITAL WARTS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 10 NORTH AMERICA DIAGNOSTIC IN GENITAL WARTS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 11 NORTH AMERICA TREATMENT IN GENITAL WARTS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 12 NORTH AMERICA TREATMENT IN GENITAL WARTS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 13 NORTH AMERICA PHARMACOLOGICAL TREATMENT IN GENITAL WARTS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 14 NORTH AMERICA NON- PHARMACOLOGICAL TREATMENT IN GENITAL WARTS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 15 NORTH AMERICA TREATMENT IN GENITAL WARTS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 16 NORTH AMERICA GENITAL WARTS MARKET, BY CAUSE, 2019-2028 (USD MILLION)

TABLE 17 NORTH AMERICA HPV 6 IN GENITAL WARTS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 18 NORTH AMERICA HPV 11 IN GENITAL WARTS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 19 NORTH AMERICA OTHERS IN GENITAL WARTS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 20 NORTH AMERICA GENITAL WARTS MARKET, BY LOCATION, 2019-2028 (USD MILLION)

TABLE 21 NORTH AMERICA VULVA IN GENITAL WARTS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 22 NORTH AMERICA CERVIX UTERI IN GENITAL WARTS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 23 NORTH AMERICA URETHRA IN GENITAL WARTS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 24 NORTH AMERICA ANUS IN GENITAL WARTS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 25 NORTH AMERICA SCROTUM IN GENITAL WARTS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 26 NORTH AMERICA GENITAL WARTS MARKET, BY GENDER, 2019-2028 (USD MILLION)

TABLE 27 NORTH AMERICA FEMALE IN GENITAL WARTS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 28 NORTH AMERICA MALE IN GENITAL WARTS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 29 NORTH AMERICA GENITAL WARTS MARKET, BY DOSAGE, 2019-2028 (USD MILLION)

TABLE 30 NORTH AMERICA CREAM IN GENITAL WARTS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 31 NORTH AMERICA GEL IN GENITAL WARTS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 32 NORTH AMERICA OINTMENT IN GENITAL WARTS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 33 NORTH AMERICA INTRAMUSCULARLY IN GENITAL WARTS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 34 NORTH AMERICA OTHERS IN GENITAL WARTS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 35 NORTH AMERICA GENITAL WARTS MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 36 NORTH AMERICA HOSPITALS IN GENITAL WARTS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 37 NORTH AMERICA DIAGNOSTIC CENTERS IN GENITAL WARTS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 38 NORTH AMERICA SURGICAL CENTERS IN GENITAL WARTS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 39 NORTH AMERICA AMBULATORY SURGICAL CENTERS IN GENITAL WARTS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 40 NORTH AMERICA OTHERS IN GENITAL WARTS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 41 NORTH AMERICA GENITAL WARTS MARKET, BY DISTRIBUTION CHANNEL 2019-2028 (USD MILLION)

TABLE 42 NORTH AMERICA DIRECT TENDER IN GENITAL WARTS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 43 NORTH AMERICA PHARMACY STORES IN GENITAL WARTS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 44 NORTH AMERICA OTHERS IN GENITAL WARTS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 45 NORTH AMERICA GENITAL WARTS MARKET, BY COUNTRY, 2019-2028 (USD MILLION)

TABLE 46 NORTH AMERICA GENITAL WARTS MARKET, BY MORPHOLOGY, 2019-2028 (USD MILLION)

TABLE 47 NORTH AMERICA GENITAL WARTS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 48 NORTH AMERICA PREVENTION IN GENITAL WARTS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 49 NORTH AMERICA GARDASIL IN GENITAL WARTS MARKET, BY COUNTRY, 2019-2028 (USD MILLION)

TABLE 50 NORTH AMERICA DIAGNOSTIC IN GENITAL WARTS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 51 NORTH AMERICA TREATMENT IN GENITAL WARTS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 52 NORTH AMERICA PHARMACOLOGICAL TREATMENT IN GENITAL WARTS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 53 NORTH AMERICA NON-PHARMACOLOGICAL TREATMENT IN GENITAL WARTS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 54 NORTH AMERICA GENITAL WARTS MARKET, BY CAUSE, 2019-2028 (USD MILLION)

TABLE 55 NORTH AMERICA GENITAL WARTS MARKET, BY LOCATION, 2019-2028 (USD MILLION)

TABLE 56 NORTH AMERICA GENITAL WARTS MARKET, BY GENDER, 2019-2028 (USD MILLION)

TABLE 57 NORTH AMERICA GENITAL WARTS MARKET, BY DOSAGE, 2019-2028 (USD MILLION)

TABLE 58 NORTH AMERICA GENITAL WARTS MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 59 NORTH AMERICA GENITAL WARTS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 60 U.S. GENITAL WARTS MARKET, BY MORPHOLOGY, 2019-2028 (USD MILLION)

TABLE 61 U.S. GENITAL WARTS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 62 U.S. PREVENTION IN GENITAL WARTS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 63 U.S. DIAGNOSTIC IN GENITAL WARTS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 64 U.S. TREATMENT IN GENITAL WARTS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 65 U.S. PHARMACOLOGICAL TREATMENT IN GENITAL WARTS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 66 U.S. NON-PHARMACOLOGICAL TREATMENT IN GENITAL WARTS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 67 U.S. GENITAL WARTS MARKET, BY CAUSE, 2019-2028 (USD MILLION)

TABLE 68 U.S. GENITAL WARTS MARKET, BY LOCATION, 2019-2028 (USD MILLION)

TABLE 69 U.S. GENITAL WARTS MARKET, BY GENDER, 2019-2028 (USD MILLION)

TABLE 70 U.S. GENITAL WARTS MARKET, BY DOSAGE, 2019-2028 (USD MILLION)

TABLE 71 U.S. GENITAL WARTS MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 72 U.S. GENITAL WARTS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 73 CANADA GENITAL WARTS MARKET, BY MORPHOLOGY, 2019-2028 (USD MILLION)

TABLE 74 CANADA GENITAL WARTS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 75 CANADA PREVENTION IN GENITAL WARTS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 76 CANADA DIAGNOSTIC IN GENITAL WARTS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 77 CANADA TREATMENT IN GENITAL WARTS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 78 CANADA PHARMACOLOGICAL TREATMENT IN GENITAL WARTS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 79 CANADA NON-PHARMACOLOGICAL TREATMENT IN GENITAL WARTS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 80 CANADA GENITAL WARTS MARKET, BY CAUSE, 2019-2028 (USD MILLION)

TABLE 81 CANADA GENITAL WARTS MARKET, BY LOCATION, 2019-2028 (USD MILLION)

TABLE 82 CANADA GENITAL WARTS MARKET, BY GENDER, 2019-2028 (USD MILLION)

TABLE 83 CANADA GENITAL WARTS MARKET, BY DOSAGE, 2019-2028 (USD MILLION)

TABLE 84 CANADA GENITAL WARTS MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 85 CANADA GENITAL WARTS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 86 MEXICO GENITAL WARTS MARKET, BY MORPHOLOGY, 2019-2028 (USD MILLION)

TABLE 87 MEXICO GENITAL WARTS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 88 MEXICO PREVENTION IN GENITAL WARTS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 89 MEXICO DIAGNOSTIC IN GENITAL WARTS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 90 MEXICO TREATMENT IN GENITAL WARTS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 91 MEXICO PHARMACOLOGICAL TREATMENT IN GENITAL WARTS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 92 MEXICO NON-PHARMACOLOGICAL TREATMENT IN GENITAL WARTS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 93 MEXICO GENITAL WARTS MARKET, BY CAUSE, 2019-2028 (USD MILLION)

TABLE 94 MEXICO GENITAL WARTS MARKET, BY LOCATION, 2019-2028 (USD MILLION)

TABLE 95 MEXICO GENITAL WARTS MARKET, BY GENDER, 2019-2028 (USD MILLION)

TABLE 96 MEXICO GENITAL WARTS MARKET, BY DOSAGE, 2019-2028 (USD MILLION)

TABLE 97 MEXICO GENITAL WARTS MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 98 MEXICO GENITAL WARTS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

 

List of Figure

LIST OF FIGURES

FIGURE 1 NORTH AMERICA GENITAL WARTS MARKET: SEGMENTATION

FIGURE 2 NORTH AMERICA GENITAL WARTS MARKET: DATA TRIANGULATION

FIGURE 3 NORTH AMERICA GENITAL WARTS MARKET: DROC ANALYSIS

FIGURE 4 NORTH AMERICA GENITAL WARTS MARKET: NORTH AMERICA VS REGIONAL ANALYSIS

FIGURE 5 NORTH AMERICA GENITAL WARTS MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 NORTH AMERICA GENITAL WARTS MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 NORTH AMERICA GENITAL WARTS MARKET: DBMR MARKET POSITION GRID

FIGURE 8 NORTH AMERICA GENITAL WARTS MARKET: VENDOR SHARE ANALYSIS

FIGURE 9 NORTH AMERICA GENITAL WARTS MARKET: MARKET END USER COVERAGE GRID

FIGURE 10 NORTH AMERICA GENITAL WARTS MARKET: SEGMENTATION

FIGURE 11 RISE OF MALE POPULATION IS EXPECTED TO DRIVE THE NORTH AMERICA GENITAL WARTS MARKET IN THE FORECAST PERIOD OF 2021 TO 2028

FIGURE 12 CAULIFLOWER-LIKE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA GENITAL WARTS MARKET IN 2021 & 2028

FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF NORTH AMERICA GENITAL WARTS MARKET

FIGURE 14 PREVALENCE OF SEXUALLY TRANSMITTED DISEASES IN THE U.S., AUSTRALIA AND CANADA

FIGURE 15 INFECTION RATE OF SEXUALLY TRANSMITTED DISEASES (STDS) IN THE FOLLOWING COUNTRIES

FIGURE 16 NORTH AMERICA GENITAL WARTS MARKET: BY MORPHOLOGY, 2020

FIGURE 17 NORTH AMERICA GENITAL WARTS MARKET: BY MORPHOLOGY, 2021-2028 (USD MILLION)

FIGURE 18 NORTH AMERICA GENITAL WARTS MARKET: BY MORPHOLOGY, CAGR (2021-2028)

FIGURE 19 NORTH AMERICA GENITAL WARTS MARKET: BY MORPHOLOGY, LIFELINE CURVE

FIGURE 20 NORTH AMERICA GENITAL WARTS MARKET: BY TYPE, 2020

FIGURE 21 NORTH AMERICA GENITAL WARTS MARKET: BY TYPE, 2021-2028 (USD MILLION)

FIGURE 22 NORTH AMERICA GENITAL WARTS MARKET: BY TYPE, CAGR (2021-2028)

FIGURE 23 NORTH AMERICA GENITAL WARTS MARKET: BY TYPE, LIFELINE CURVE

FIGURE 24 NORTH AMERICA GENITAL WARTS MARKET: BY CAUSE, 2020

FIGURE 25 NORTH AMERICA GENITAL WARTS MARKET: BY CAUSE, 2021-2028 (USD MILLION)

FIGURE 26 NORTH AMERICA GENITAL WARTS MARKET: BY CAUSE, CAGR (2021-2028)

FIGURE 27 NORTH AMERICA GENITAL WARTS MARKET: BY CAUSE, LIFELINE CURVE

FIGURE 28 NORTH AMERICA GENITAL WARTS MARKET: BY LOCATION 2020

FIGURE 29 NORTH AMERICA GENITAL WARTS MARKET: BY LOCATION 2021-2028 (USD MILLION)

FIGURE 30 NORTH AMERICA GENITAL WARTS MARKET: BY LOCATION CAGR (2021-2028)

FIGURE 31 NORTH AMERICA GENITAL WARTS MARKET: BY LOCATION, LIFELINE CURVE

FIGURE 32 NORTH AMERICA GENITAL WARTS MARKET: BY GENDER 2020

FIGURE 33 NORTH AMERICA GENITAL WARTS MARKET: BY GENDER 2021-2028 (USD MILLION)

FIGURE 34 NORTH AMERICA GENITAL WARTS MARKET: BY GENDER CAGR (2021-2028)

FIGURE 35 NORTH AMERICA GENITAL WARTS MARKET: BY GENDER, LIFELINE CURVE

FIGURE 36 NORTH AMERICA GENITAL WARTS MARKET: BY DOSAGE 2020

FIGURE 37 NORTH AMERICA GENITAL WARTS MARKET: BY DOSAGE 2021-2028 (USD MILLION)

FIGURE 38 NORTH AMERICA GENITAL WARTS MARKET: BY DOSAGE CAGR (2021-2028)

FIGURE 39 NORTH AMERICA GENITAL WARTS MARKET: BY DOSAGE, LIFELINE CURVE

FIGURE 40 NORTH AMERICA GENITAL WARTS MARKET: BY END USER, 2020

FIGURE 41 NORTH AMERICA GENITAL WARTS MARKET: BY END USER, 2021-2028 (USD MILLION)

FIGURE 42 NORTH AMERICA GENITAL WARTS MARKET: BY END USER, CAGR (2021-2028)

FIGURE 43 NORTH AMERICA GENITAL WARTS MARKET: BY END USER, LIFELINE CURVE

FIGURE 44 NORTH AMERICA GENITAL WARTS MARKET: BY DISTRIBUTION CHANNEL, 2020

FIGURE 45 NORTH AMERICA GENITAL WARTS MARKET: BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)

FIGURE 46 NORTH AMERICA GENITAL WARTS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)

FIGURE 47 NORTH AMERICA GENITAL WARTS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 48 NORTH AMERICA GENITAL WARTS MARKET: SNAPSHOT (2020)

FIGURE 49 NORTH AMERICA GENITAL WARTS MARKET: BY COUNTRY (2020)

FIGURE 50 NORTH AMERICA GENITAL WARTS MARKET: BY COUNTRY (2020 & 2028)

FIGURE 51 NORTH AMERICA GENITAL WARTS MARKET: BY PRODUCT (2021-2028)

FIGURE 52 NORTH AMERICA GENITAL WARTS MARKET: BY MORPHOLOGY (2021-2028)

FIGURE 53 NORTH AMERICA GENITAL WARTS MARKET: COMPANY SHARE 2020 (%)

 

View Infographics

LIST OF FIGURES

FIGURE 1 NORTH AMERICA GENITAL WARTS MARKET: SEGMENTATION

FIGURE 2 NORTH AMERICA GENITAL WARTS MARKET: DATA TRIANGULATION

FIGURE 3 NORTH AMERICA GENITAL WARTS MARKET: DROC ANALYSIS

FIGURE 4 NORTH AMERICA GENITAL WARTS MARKET: NORTH AMERICA VS REGIONAL ANALYSIS

FIGURE 5 NORTH AMERICA GENITAL WARTS MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 NORTH AMERICA GENITAL WARTS MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 NORTH AMERICA GENITAL WARTS MARKET: DBMR MARKET POSITION GRID

FIGURE 8 NORTH AMERICA GENITAL WARTS MARKET: VENDOR SHARE ANALYSIS

FIGURE 9 NORTH AMERICA GENITAL WARTS MARKET: MARKET END USER COVERAGE GRID

FIGURE 10 NORTH AMERICA GENITAL WARTS MARKET: SEGMENTATION

FIGURE 11 RISE OF MALE POPULATION IS EXPECTED TO DRIVE THE NORTH AMERICA GENITAL WARTS MARKET IN THE FORECAST PERIOD OF 2021 TO 2028

FIGURE 12 CAULIFLOWER-LIKE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA GENITAL WARTS MARKET IN 2021 & 2028

FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF NORTH AMERICA GENITAL WARTS MARKET

FIGURE 14 PREVALENCE OF SEXUALLY TRANSMITTED DISEASES IN THE U.S., AUSTRALIA AND CANADA

FIGURE 15 INFECTION RATE OF SEXUALLY TRANSMITTED DISEASES (STDS) IN THE FOLLOWING COUNTRIES

FIGURE 16 NORTH AMERICA GENITAL WARTS MARKET: BY MORPHOLOGY, 2020

FIGURE 17 NORTH AMERICA GENITAL WARTS MARKET: BY MORPHOLOGY, 2021-2028 (USD MILLION)

FIGURE 18 NORTH AMERICA GENITAL WARTS MARKET: BY MORPHOLOGY, CAGR (2021-2028)

FIGURE 19 NORTH AMERICA GENITAL WARTS MARKET: BY MORPHOLOGY, LIFELINE CURVE

FIGURE 20 NORTH AMERICA GENITAL WARTS MARKET: BY TYPE, 2020

FIGURE 21 NORTH AMERICA GENITAL WARTS MARKET: BY TYPE, 2021-2028 (USD MILLION)

FIGURE 22 NORTH AMERICA GENITAL WARTS MARKET: BY TYPE, CAGR (2021-2028)

FIGURE 23 NORTH AMERICA GENITAL WARTS MARKET: BY TYPE, LIFELINE CURVE

FIGURE 24 NORTH AMERICA GENITAL WARTS MARKET: BY CAUSE, 2020

FIGURE 25 NORTH AMERICA GENITAL WARTS MARKET: BY CAUSE, 2021-2028 (USD MILLION)

FIGURE 26 NORTH AMERICA GENITAL WARTS MARKET: BY CAUSE, CAGR (2021-2028)

FIGURE 27 NORTH AMERICA GENITAL WARTS MARKET: BY CAUSE, LIFELINE CURVE

FIGURE 28 NORTH AMERICA GENITAL WARTS MARKET: BY LOCATION 2020

FIGURE 29 NORTH AMERICA GENITAL WARTS MARKET: BY LOCATION 2021-2028 (USD MILLION)

FIGURE 30 NORTH AMERICA GENITAL WARTS MARKET: BY LOCATION CAGR (2021-2028)

FIGURE 31 NORTH AMERICA GENITAL WARTS MARKET: BY LOCATION, LIFELINE CURVE

FIGURE 32 NORTH AMERICA GENITAL WARTS MARKET: BY GENDER 2020

FIGURE 33 NORTH AMERICA GENITAL WARTS MARKET: BY GENDER 2021-2028 (USD MILLION)

FIGURE 34 NORTH AMERICA GENITAL WARTS MARKET: BY GENDER CAGR (2021-2028)

FIGURE 35 NORTH AMERICA GENITAL WARTS MARKET: BY GENDER, LIFELINE CURVE

FIGURE 36 NORTH AMERICA GENITAL WARTS MARKET: BY DOSAGE 2020

FIGURE 37 NORTH AMERICA GENITAL WARTS MARKET: BY DOSAGE 2021-2028 (USD MILLION)

FIGURE 38 NORTH AMERICA GENITAL WARTS MARKET: BY DOSAGE CAGR (2021-2028)

FIGURE 39 NORTH AMERICA GENITAL WARTS MARKET: BY DOSAGE, LIFELINE CURVE

FIGURE 40 NORTH AMERICA GENITAL WARTS MARKET: BY END USER, 2020

FIGURE 41 NORTH AMERICA GENITAL WARTS MARKET: BY END USER, 2021-2028 (USD MILLION)

FIGURE 42 NORTH AMERICA GENITAL WARTS MARKET: BY END USER, CAGR (2021-2028)

FIGURE 43 NORTH AMERICA GENITAL WARTS MARKET: BY END USER, LIFELINE CURVE

FIGURE 44 NORTH AMERICA GENITAL WARTS MARKET: BY DISTRIBUTION CHANNEL, 2020

FIGURE 45 NORTH AMERICA GENITAL WARTS MARKET: BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)

FIGURE 46 NORTH AMERICA GENITAL WARTS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)

FIGURE 47 NORTH AMERICA GENITAL WARTS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 48 NORTH AMERICA GENITAL WARTS MARKET: SNAPSHOT (2020)

FIGURE 49 NORTH AMERICA GENITAL WARTS MARKET: BY COUNTRY (2020)

FIGURE 50 NORTH AMERICA GENITAL WARTS MARKET: BY COUNTRY (2020 & 2028)

FIGURE 51 NORTH AMERICA GENITAL WARTS MARKET: BY PRODUCT (2021-2028)

FIGURE 52 NORTH AMERICA GENITAL WARTS MARKET: BY MORPHOLOGY (2021-2028)

FIGURE 53 NORTH AMERICA GENITAL WARTS MARKET: COMPANY SHARE 2020 (%)

 

CHOOSE LICENCE TYPE
  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 8500.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19